“Patrick is an innovative executive with extensive experience in drug development. He is a pragmatic leader who was able to drive major changes and reshape the image of Clinical Data Management and Programming. Within 18 months, he automated 50% of the manual reviews, reduced DB lock cycle time and further secured data quality by aligning data cleaning practices to the study risks and monitoring strategies. He was also able to attract highly talented leaders and built a strong organization. Patrick is a genuine leader of high integrity, great collaborator and an asset to any organization. ”
Patrick Nadolny
Gentilly, Île-de-France, France
7 k abonnés
+ de 500 relations
À propos
A results-driven, innovative TOP EXECUTIVE with extensive experience in Drug Development…
Activité
-
🌸 Celebrating International Women’s Day with Gratitude 🌸 Today, I want to take a moment to honor someone who is not just an expert in her field…
🌸 Celebrating International Women’s Day with Gratitude 🌸 Today, I want to take a moment to honor someone who is not just an expert in her field…
Aimé par Patrick Nadolny
-
Call for USDM Trainers! The TransCelerate BioPharma Digital Data Flow (DDF) initiative along with CDISC’s development of the Unified Study…
Call for USDM Trainers! The TransCelerate BioPharma Digital Data Flow (DDF) initiative along with CDISC’s development of the Unified Study…
Aimé par Patrick Nadolny
-
🌸 International Women's Day 2025 | #AccelerateAction #Equally 🌸 On 05th Mar, ICON plc, Bangalore, we celebrated the resilience, strength, and…
🌸 International Women's Day 2025 | #AccelerateAction #Equally 🌸 On 05th Mar, ICON plc, Bangalore, we celebrated the resilience, strength, and…
Aimé par Patrick Nadolny
Expérience
Formation
-
Conservatoire National des Arts et Métiers
-
I completed a thesis on natural language analysis. I created a coding system using artificial intelligence algorithms analyzing semantic of English verbatim.
-
-
Publications
-
Historical Benchmarks for Quality Tolerance Limits Parameters in Clinical Trials
DIA TIRS
Background: In 2016, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use updated its efficacy guideline for good clinical practice and introduced quality tolerance limits (QTLs) as quality control in clinical trials. Previously, TransCelerate proposed a framework for QTL implementation and parameters. Historical data can be important in helping to determine QTL thresholds in new clinical trials
Autres auteursVoir la publication -
An Industry Position Paper: Audit Trail Review, a key tool to ensure data integrity
SCDM and eClinical Forum
This paper outlines an industry perspective on maximizing the value of implementing the targeted, routine review of these extremely large datasets. It provides recommendations on risk-based use cases for audit trail review (ATR) and the corresponding desired reporting criteria, with suggestions on when to use visualizations and exception report listings to generate key, actionable insights. It contains practical implementation guidance, covering the people, processes and technology needed to…
This paper outlines an industry perspective on maximizing the value of implementing the targeted, routine review of these extremely large datasets. It provides recommendations on risk-based use cases for audit trail review (ATR) and the corresponding desired reporting criteria, with suggestions on when to use visualizations and exception report listings to generate key, actionable insights. It contains practical implementation guidance, covering the people, processes and technology needed to execute ATRs effectively. The authors also take a deep dive into the technical aspects of what constitutes an audit trail, and how collecting and preparing audit trail data is fundamental to successful ATR capability.
Autres auteursVoir la publication -
What Is Your AI Road Map To Revolutionize Drug Development?
Clinical Leader
This article will share insights on how to pragmatically initiate an AI journey using the evolution of clinical data management as an example.
-
Reflection Paper on the Evolution of Clinical Data Management to Clinical Data Science (Part 3: The evolution of the CDM Role)
Society For Clinical Data Management
This paper provide insights on how CDM professionals who have successfully and passionately contributed to the credibility of CDM can evolve their skillsets and competencies to cope with the increasing complexities of clinical research which demands novel approaches maximizing the potential of available technologies.
Autres auteursVoir la publication -
Quality Tolerance Limits: Framework for Successful Implementation in Clinical Development
DIA (TransCelerate)
TransCelerate BioPharma Inc.’s interpretations of Clinical Guidances & Regulations Initiative’s paper on a proposed definition of a #QTL, process map/steps and examples of QTL parameters
Autres auteursVoir la publication -
Reflection Paper on the Evolution of Clinical Data Management to Clinical Data Science (Part 2: Technology Enablers)
Society For Clinical Data Management
In seeking to build upon the previous publication on the industry trends on the evolution of Clinical Data Management to Clinical Data Science, this second chapter focuses on the technologies enabling this evolution and allowing organizations to efficiently manage the 5Vs of clinical data (i.e., Variety, Volume, Velocity, Veracity, and Value).
This second paper also shares insights and lessons learned from leaders, pioneers and early adopters of those emerging technologies.
Autres auteursVoir la publication -
Reflection Paper on the Evolution of Clinical Data Management to Clinical Data Science
Society For Clinical Data Management
The Evolution of Clinical Data Management to Clinical Data Science: A Reflection Paper on the impact of the Clinical Research industry trends on Clinical Data Management. In the context of this reflection paper, Clinical Data Science is defined as the strategic discipline enabling data driven Clinical Research approaches and ensuring subject protection as well as the reliability and credibility of trial results. Clinical Data Science encompasses processes, domain expertise, technologies, data…
The Evolution of Clinical Data Management to Clinical Data Science: A Reflection Paper on the impact of the Clinical Research industry trends on Clinical Data Management. In the context of this reflection paper, Clinical Data Science is defined as the strategic discipline enabling data driven Clinical Research approaches and ensuring subject protection as well as the reliability and credibility of trial results. Clinical Data Science encompasses processes, domain expertise, technologies, data analytics and Good Clinical Data Management Practices essential to prompt decision making throughout the life cycle of Clinical Research.
Autres auteursVoir la publication -
Detecting Data Quality Issues in Clinical Trials: Current Practices and Recommendations
DIA (TransCelerate)
This article focuses on detecting data quality issues, irrespective of origin or motive. Early detection of data quality issues are important so that corrective actions taken can be implemented during the conduct of the trial, recurrence can be prevented, and data quality can be preserved.
Autres auteursVoir la publication -
2016 DIA Authors of the Year Award: Evaluating Source Data Verification as a Quality Control Measure in Clinical Trials
DIA (TransCelerate)
The manuscript examines the value of Source Data Verification (SDV) and concludes that the SDV has limited value as a quality control measure. TransCelerate's RBM methodology proposes shifting monitoring processes from an excessive concentration on SDV to comprehensive, risk-driven monitoring that uses a combination of central, off-site and on-site monitoring activities.
Autres auteursVoir la publication
Prix et distinctions
-
Authors of the Year Award
DIA
2016 DIA Authors of the Year Award: Evaluating Source Data Verification as a Quality Control Measure in Clinical Trials (a TransCelerate paper)
Langues
-
French
Bilingue ou langue natale
-
English
Bilingue ou langue natale
Recommandations reçues
-
Membre LinkedIn
8 personnes ont recommandé Patrick
Inscrivez-vous pour y accéderPlus d’activités de Patrick
-
The future of Clinical Data Science starts here! 🌍✨ Excited to bring SCDM’s expertise to KU Leuven University, inspiring the next generation of…
The future of Clinical Data Science starts here! 🌍✨ Excited to bring SCDM’s expertise to KU Leuven University, inspiring the next generation of…
Aimé par Patrick Nadolny
-
Happy to share that I attended the Medidata Hyderabad Innovation Day on Thursday, February 27, 2025! Thank you to Medidata for organizing this event…
Happy to share that I attended the Medidata Hyderabad Innovation Day on Thursday, February 27, 2025! Thank you to Medidata for organizing this event…
Aimé par Patrick Nadolny
-
Had the most amazing day today at Special Olympics NJ unified Youth Summit: “Women in Leadership”. Spoke about my career, my role as chairwoman of…
Had the most amazing day today at Special Olympics NJ unified Youth Summit: “Women in Leadership”. Spoke about my career, my role as chairwoman of…
Aimé par Patrick Nadolny
-
While we work hard to make future editions even more impactful, take a look at what our past attendees have to say about SCDM #India24! This event…
While we work hard to make future editions even more impactful, take a look at what our past attendees have to say about SCDM #India24! This event…
Aimé par Patrick Nadolny
-
If you are at SCOPE, I encourage you to check out VCT and their booth.
If you are at SCOPE, I encourage you to check out VCT and their booth.
Aimé par Patrick Nadolny
Autres profils similaires
Autres personnes nommées Patrick Nadolny
3 autres personnes nommées Patrick Nadolny sont sur LinkedIn
Autres personnes nommées Patrick Nadolny